TL;DR
Miami anchors a growing South Florida biotech cluster centered on University of Miami spinouts, Bascom Palmer Eye Institute (ophthalmic device innovation), and the Sylvester Comprehensive Cancer Center. The cluster carries distinctive insurance characteristics: ophthalmic device exposure, frequent Latin America clinical trial site arrangements, and a relatively light Florida regulatory overlay.
Miami biotech
Miami biotech insurance - University of Miami, Bascom Palmer, South Florida cluster.
Miami and the broader South Florida region have built a meaningful biotech cluster centered on University of Miami Miller School of Medicine, Bascom Palmer Eye Institute (one of the world's leading ophthalmic care and research institutions), and the Sylvester Comprehensive Cancer Center. The cluster carries distinctive characteristics including ophthalmic device focus and frequent Latin America clinical trial site arrangements that affect insurance program design.
Cluster characteristics
Ophthalmic device, Latin America trial sites, oncology.
Bascom Palmer Eye Institute contributes ophthalmic device spinouts across surgical instruments, intraocular lenses, drug-delivery devices, and retinal therapeutics. Ophthalmic device insurance carries implantable claim tail considerations and specific ASC (ambulatory surgical center) purchase contract demands.
Sylvester Comprehensive Cancer Center contributes oncology spinouts. Standard clinical-stage architecture with attention to Sylvester licensing terms.
University of Miami Miller School of Medicine contributes broader clinical-stage spinouts. Many Miami biotech operators run clinical trials at Latin America sites - the insurance program needs to address country-specific local insurance regulatory regimes for any non-US trial activity.
Miami biotech coverage review